Innolake Biopharm is a clinical stage biotech company, dedicated to developing innovative medicines against cancer and autoimmune diseases to improve the life of patients around the world. Innolake was co-founded by two industry veterans, Dr. Mingde Xia (former Sr. Director of Global External Innovation at Johnson & Johnson) and Mr. Robert Chen (former founding member and Executive Vice President of Genor Biopharma, one of pioneering therapeutic antibody companies in China) in 2020. The company debuted with a top-tier and enthusiastic scientific & clinical development team and $40 million Series Pre-A. By continuously building proprietary technology platforms and R&D capabilities, Innolake places innovation at the cornerstone of its overall strategy. Through in-house R&D and partnering with MNCs and overseas biotech companies, Innolake has established a robust pipeline with more than ten first-in-class and best-in-class drug candidates, two of which have entered the clinical stage. Recently, Innolake was recognized as a “Chinese Next Unicorn” enterprise and listed on ”2021 China Biopharmaceutical Industry Innovation Top100 List”.
Location: China, Zhejiang, Hangzhou City
Employees: 51-200
Founded date: 2020